Answers are grounded in this paper and cite their sources.
Background: Following the rapid growth in genetic information related to drug responses, the urgent need to organize this information for clinical use has arisen.The current databases used in Korea lack information about drug responses as they pertain to specific ethnic groups, including Koreans, and the frequency of genomic variants.This study aimed to develop a pharmacogenetics-alternative allele frequency (AAF) database (PharmGAF DB) in South Korea to address this issue.Methods: Drugs were selected from the drug response database of the Korean Ministry of Food and Drug Safety by studying various pharmacogenetic guidelines such as Clinical Pharmacogenetics Implementation Consortium, Dutch Pharmacogenetics Working Group, and Canadian Pharmacogenomics Network for Drug Safety and drug labels accepted by various health authorities such as the United States Food and Drug Administration, European Medicines Agency, and the Pharmaceuticals and Medical Devices Agency.Information on drug responses was collected and updated for a set of selected drugs from pharmacogenetics literature over the past ten years.AAF information was gathered from the Korean Reference Genome Database, the single nucleotide polymorphism database, and the Allele Frequency Net Database. Results:In total, 80 drugs were investigated, and the pharmacogenomic effects of 142 variants in relation to these drugs were updated.Pharmacokinetic effects were found for 51 variants and pharmacodynamic effects were found for 111 variants.AAF information was collected for these variants in Korean, East Asian, and Caucasian populations.Variants for which AAF significantly differed between Koreans and Caucasians were identified.Finally, PharmGAF DB was created by combining information on the pharmacogenomic effects and the AAF. Conclusion:The newly developed database, PharmGAF DB, was created by merging information on how drug responses relate to genotypes and allele frequencies among different ethnic groups.PharmGAF DB should improve drug efficacy and reduce the occurrence of side effects by supporting the implementation of precision medicine in clinical practice.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: